European Companies Search Engine
EU funding (€464,600): Membrane protein integrated technologies development for drug design Hor13 Nov 2018 EU Research and Innovation programme "Horizon"
Text
Membrane protein integrated technologies development for drug design
The aim of the ProMeTeus Consortium is to provide high-quality multidisciplinary knowledge through training and research on the development of protein studies as molecular tools for drug development and drug delivery. The focus of the action is the creation of a synergistic pipeline to yield target membrane protein structures and characterization and bioactive molecules design, harnessing the complementary skills from Academic and SME participants. We propose to join key expertise in protein structural biology and biochemistry with state-of-the art facilities for membrane protein high-throughput target selection and expression. A strategic contribution will be provided by SME in key technologies (virtual screening, detergent science, organic synthesis and biotech) and in exploitation, dissemination and resource acquisition skills. We will deliver crucial data for the development of new leads for health issues such as the design of new antibiotics or new strategies for theranostics and foster a synergistic approach to novel bioactive compounds development between academic and SME. The acquisition of new skill from staff will come from secondments aimed at training on research topics not available at the home institutions and attendance to courses, workshops, seminar and conferences. In an era where academic institutions are called to participate actively in technological and industrial development and SME provide services to and benefit of the wide breadth of academic research programs, we will foster a culture of synergistic exchange and cross-fertilization. The consortium consists of 9 beneficiaries and 2 partners , of which 7 are academic and 4 are SME. During 4 years 16 ESRs, 6 ERs and 2 research managers will be seconded to 1 Institutions, where they will be supported by a team of leading scientists. The Network will promote the integration of academic and SME in combining excellent science with entrepreneurial approach and high-throughput methodologies.
Funded Companies:
| Company name | Funding amount |
| NEW YORK STRUCTURAL BIOLOGY CENTER Inc. | ? |
| Calixar | €0.00 |
| Extremochem Lda. | €50,600 |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | €9,200.00 |
| Instituto de Biologia Experimental e Tecnologica | €82,800 |
| Molirom Srl | €18,400.00 |
| Sapienza Innovazione Consorzio | €9,200.00 |
| Universidade Nova de Lisboa | €82,800 |
| Universita Degli Studi Di Roma LA Sapienza | €128,800 |
| Universita Politecnica Delle Marche | €82,800 |
Source: https://cordis.europa.eu/project/id/823780
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: New York Structural Biology Center, NEW York, United States.
The visualizations for "NEW YORK STRUCTURAL BIOLOGY CENTER Inc. - EU funding (€464,600): Membrane protein integrated technologies development for drug design"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
